18:56 , Jul 13, 2018 |  BC Week In Review  |  Clinical News

Filgotinib meets in Phase II for psoriatic arthritis

Gilead Sciences Inc. (NASDAQ:GILD) and Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) said in May that once-daily 200 mg oral filgotinib (GLPG0634, GS-6034) met the primary endpoint of improving the proportion of patients with a 20% improvement in...
19:09 , Apr 20, 2018 |  BC Week In Review  |  Company News

Target ALS and partners launch biomarker study

Target ALS Foundation (New York, N.Y.) is partnering with the Muscular Dystrophy Association (MDA) (Chicago, Ill.), the CReATe Consortium and 10 industry partners to conduct a study to validate biomarker candidates for amyotrophic lateral sclerosis....
20:26 , Apr 19, 2018 |  BC Extra  |  Company News

Target ALS, partners launch biomarker study

Target ALS Foundation is partnering with the Muscular Dystrophy Association (MDA), the CReATe Consortium and 10 industry partners to conduct a study to validate biomarker candidates for amyotrophic lateral sclerosis. The study will seek to...
07:00 , May 26, 2014 |  BC Week In Review  |  Clinical News

Aldeyra Therapeutics preclinical data

In reconstructed human epidermis under dry skin conditions, topical 0.05% NS2 significantly reduced malondialdehyde (MDA) levels vs. untreated controls (p<0.01). Aldeyra said that MDA levels have been shown to be elevated in a variety of...
07:00 , Jun 3, 2013 |  BioCentury  |  Product Development

The DMD landscape

Three companies are vying to gain the first approved drug for Duchenne muscular dystrophy in a race that has seen one company's stock soar 309% over the past year and the other two companies file...
00:39 , Sep 19, 2012 |  BC Extra  |  Politics & Policy

MDA names Derks president, CEO

The Muscular Dystrophy Association hired Steven Derks as president and CEO. He succeeds Gerald Weinberg, who retired at the end of last year. The not-for-profit said Derks will remain at the American Cancer Society, where...
07:00 , Oct 20, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Ophthalmic disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Ophthalmic disease Age-related macular degeneration (AMD) Complement factor H (CFH); malondialdehyde (MDA) Mouse and in vitro studies suggest increasing CFH binding to...
07:00 , Oct 20, 2011 |  BC Innovations  |  Targets & Mechanisms

Factor H complements AMD

Researchers in the EU and the U.S. have found what could be the mechanistic underpinnings of the increased risk for age-related macular degeneration in individuals carrying a common polymorphism in the gene for complement factor...
08:00 , Nov 9, 2009 |  BC Week In Review  |  Clinical News

Lu AA24493: Phase IIa started

Lundbeck began a double-blind, placebo-controlled, European Phase IIa trial to evaluate IV Lu AA24493 in 35-40 patients given for 2 weeks. The company licensed worldwide rights to Lu AA24493 for CNS-related indications from Warren in...
08:00 , Nov 2, 2009 |  BioCentury  |  Strategy

Building Qiagen

Building Qiagen Since Peer Schatz took over as CEO in early 2004, Qiagen N.V. (Xetra:QIA; NASDAQ:QGEN) has seen its revenues and adjusted operating income grow at CAGRs of 21% and 27%, respectively. Molecular diagnostics has...